Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018936007> ?p ?o ?g. }
- W2018936007 endingPage "6" @default.
- W2018936007 startingPage "1" @default.
- W2018936007 abstract "Pre-eclampsia (P-Ec) is a complex multisystem disorder of unknown aetiology reported to occur in about 6% to 8% of all pregnancies throughout the world. This disease is associated with fibrin deposition and occlusive lesions in placental vessels. Pro-thrombin activatable fibrinolysis inhibitor (pro-TAFI) is a relatively recently described glycoprotein that can be converted into its active form (TAFIa) by thrombin, thrombin–thrombomodulin and plasmin. TAFIa potentially inhibits fibrinolysis by removing C-terminal lysine and arginine residues from fibrin. These residues are required for adsorption of tissue-type plasminogen activator (t-PA) and plasminogen to fibrin. Therefore, TAFIa decreases plasmin formation and protects the fibrin clot against lysis. An increased of pro-TAFI/TAFIa levels has been reported in some clinical conditions associated with thrombotic tendency, as type II diabetes mellitus, deep vein thrombosis and symptomatic artery disease. Few studies have investigated pro-TAFI/TAFIa in normal or complicated pregnancy but contrasting results were reported. Understanding the role of pro-TAFI/TAFIa in the pathogenesis of P-Ec can hold great promise for improving P-Ec management. In this context, a large-scale study evaluating plasma TAFI antigen and activity, its synthesis and metabolism in pre-eclamptic women is required. Recently new selective TAFIa inhibitors have been developed. The design of a new therapy to treat and/or prevent P-Ec, based on successful use of TAFIa inhibitors, may have significant clinical ramifications." @default.
- W2018936007 created "2016-06-24" @default.
- W2018936007 creator A5032528930 @default.
- W2018936007 creator A5040956604 @default.
- W2018936007 creator A5042214004 @default.
- W2018936007 date "2007-03-01" @default.
- W2018936007 modified "2023-09-25" @default.
- W2018936007 title "Thrombin activatable fibrinolysis inhibitor (TAFI): A role in pre-eclampsia?" @default.
- W2018936007 cites W112254320 @default.
- W2018936007 cites W1514226843 @default.
- W2018936007 cites W1554280422 @default.
- W2018936007 cites W187187498 @default.
- W2018936007 cites W191436139 @default.
- W2018936007 cites W1933167659 @default.
- W2018936007 cites W1954576125 @default.
- W2018936007 cites W1963133109 @default.
- W2018936007 cites W1967136577 @default.
- W2018936007 cites W1969778347 @default.
- W2018936007 cites W1974801923 @default.
- W2018936007 cites W1977497608 @default.
- W2018936007 cites W1978010631 @default.
- W2018936007 cites W1979516217 @default.
- W2018936007 cites W1980312970 @default.
- W2018936007 cites W1980470187 @default.
- W2018936007 cites W1984323794 @default.
- W2018936007 cites W1984565472 @default.
- W2018936007 cites W1986481652 @default.
- W2018936007 cites W1991306519 @default.
- W2018936007 cites W1996945382 @default.
- W2018936007 cites W2000397813 @default.
- W2018936007 cites W2005134321 @default.
- W2018936007 cites W2005463486 @default.
- W2018936007 cites W2011784685 @default.
- W2018936007 cites W2015842385 @default.
- W2018936007 cites W2020298560 @default.
- W2018936007 cites W2020361082 @default.
- W2018936007 cites W2023946767 @default.
- W2018936007 cites W2024085589 @default.
- W2018936007 cites W2024096807 @default.
- W2018936007 cites W2029160049 @default.
- W2018936007 cites W2029453461 @default.
- W2018936007 cites W2035474793 @default.
- W2018936007 cites W2038723412 @default.
- W2018936007 cites W2038728613 @default.
- W2018936007 cites W2045054462 @default.
- W2018936007 cites W2046016697 @default.
- W2018936007 cites W2046290900 @default.
- W2018936007 cites W2047683992 @default.
- W2018936007 cites W2050736179 @default.
- W2018936007 cites W2054169150 @default.
- W2018936007 cites W2055075407 @default.
- W2018936007 cites W2057952723 @default.
- W2018936007 cites W2066822578 @default.
- W2018936007 cites W2069436323 @default.
- W2018936007 cites W2069850959 @default.
- W2018936007 cites W2073273161 @default.
- W2018936007 cites W2077242279 @default.
- W2018936007 cites W2079175463 @default.
- W2018936007 cites W2079337300 @default.
- W2018936007 cites W2080840742 @default.
- W2018936007 cites W2083571158 @default.
- W2018936007 cites W2084042728 @default.
- W2018936007 cites W2084688828 @default.
- W2018936007 cites W2091050097 @default.
- W2018936007 cites W2092383088 @default.
- W2018936007 cites W2094814371 @default.
- W2018936007 cites W2110050667 @default.
- W2018936007 cites W2112064946 @default.
- W2018936007 cites W2118564724 @default.
- W2018936007 cites W2120968905 @default.
- W2018936007 cites W2133640678 @default.
- W2018936007 cites W2144618814 @default.
- W2018936007 cites W2163446837 @default.
- W2018936007 cites W2165776504 @default.
- W2018936007 cites W2172069911 @default.
- W2018936007 cites W2412293557 @default.
- W2018936007 cites W2469405187 @default.
- W2018936007 cites W2897901863 @default.
- W2018936007 cites W3160565403 @default.
- W2018936007 cites W4211187622 @default.
- W2018936007 cites W4232212947 @default.
- W2018936007 cites W4235037703 @default.
- W2018936007 cites W4379250858 @default.
- W2018936007 doi "https://doi.org/10.1016/j.cca.2006.10.014" @default.
- W2018936007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17184758" @default.
- W2018936007 hasPublicationYear "2007" @default.
- W2018936007 type Work @default.
- W2018936007 sameAs 2018936007 @default.
- W2018936007 citedByCount "6" @default.
- W2018936007 countsByYear W20189360072013 @default.
- W2018936007 countsByYear W20189360072017 @default.
- W2018936007 crossrefType "journal-article" @default.
- W2018936007 hasAuthorship W2018936007A5032528930 @default.
- W2018936007 hasAuthorship W2018936007A5040956604 @default.
- W2018936007 hasAuthorship W2018936007A5042214004 @default.
- W2018936007 hasConcept C126322002 @default.
- W2018936007 hasConcept C181199279 @default.
- W2018936007 hasConcept C185592680 @default.